PBMC-based Leukocyte Immunotherapy

NCT06172894 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: APN401

Sponsor

invIOs GmbH